Follow the people · Insider
Khurram Jamil
Khurram Jamil files insider transactions with the SEC as a chief medical officer of Galectin Therapeutics (GALT). We hold 9 disclosed purchases and sales filed since 5 August 2024, 4 of them in the last 90 days.
- Files forGALT
- Disclosed buys and sells9 in all, 4 in the last 90 days
- Last disclosure16 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 August 2024 — 14 July 2026Chief Medical Officer · Galectin Therapeutics (GALT)62 Form 4 lines · source: SEC Form 4
Everything they disclosed
62 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 16,250 shares of Galectin TherapeuticsSEC Form 416 July 2026Common Stock · traded 14 July 2026 · filed 16 July 2026
- ▼ sold on the open market 16,250 shares of Galectin TherapeuticsSEC Form 416 July 2026Common Stock · traded 14 July 2026 · filed 16 July 2026
- exercised options over 16,250 shares of Galectin Therapeutics (a derivative holding)SEC Form 416 July 2026Stock option (right to buy) · traded 14 July 2026 · filed 16 July 2026
- exercised options over 2,037 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 2,037 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- exercised options over 2,533 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- ▼ sold on the open market 2,533 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 26 June 2026 · filed 30 June 2026
- exercised options over 47,467 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- ▼ sold on the open market 47,467 shares of Galectin TherapeuticsSEC Form 430 June 2026Common Stock · traded 29 June 2026 · filed 30 June 2026
- exercised options over 2,037 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 June 2026Stock option (right to buy) · traded 26 June 2026 · filed 30 June 2026
- exercised options over 2,533 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option (right to buy) · traded 26 June 2026 · filed 30 June 2026
- exercised options over 47,467 shares of Galectin Therapeutics (a derivative holding)SEC Form 430 June 2026Stock Option (right to buy) · traded 29 June 2026 · filed 30 June 2026
- exercised options over 7,557 shares of Galectin TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 7,557 shares of Galectin TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 7,557 shares of Galectin Therapeutics (a derivative holding)SEC Form 425 June 2026Stock option (right to buy) · traded 23 June 2026 · filed 25 June 2026
- exercised options over 568 shares of Galectin TherapeuticsSEC Form 428 May 2026Common Stock · traded 26 May 2026 · filed 28 May 2026
- ▼ sold on the open market 568 shares of Galectin TherapeuticsSEC Form 428 May 2026Common Stock · traded 26 May 2026 · filed 28 May 2026
- exercised options over 568 shares of Galectin Therapeutics (a derivative holding)SEC Form 428 May 2026Stock option (right to buy) · traded 26 May 2026 · filed 28 May 2026
- was granted 65,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Stock option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- was granted 100,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Restricted Stock Unit · traded 16 January 2026 · filed 21 January 2026
- was granted 65,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Stock option (right to buy) · traded 16 January 2026 · filed 21 January 2026
- was granted 100,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 421 January 2026Restricted Stock Unit · traded 16 January 2026 · filed 21 January 2026
- exercised options over 60,000 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 13,055 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 25,499 shares of Galectin TherapeuticsSEC Form 46 January 2026Common stock · traded 5 January 2026 · filed 6 January 2026
- exercised options over 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 January 2026Restricted Stock Unit · traded 1 January 2026 · filed 6 January 2026
- ▼ sold on the open market 21,446 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 6 January 2026 · filed 6 January 2026
- exercised options over 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 46 January 2026Restricted Stock Unit · traded 1 January 2026 · filed 6 January 2026
- exercised options over 60,000 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 13,055 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 2 January 2026 · filed 6 January 2026
- ▼ sold on the open market 25,499 shares of Galectin TherapeuticsSEC Form 46 January 2026Common stock · traded 5 January 2026 · filed 6 January 2026
- ▼ sold on the open market 21,446 shares of Galectin TherapeuticsSEC Form 46 January 2026Common Stock · traded 6 January 2026 · filed 6 January 2026
- exercised options over 8,125 shares of Galectin TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- ▼ sold on the open market 8,125 shares of Galectin TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- exercised options over 8,125 shares of Galectin Therapeutics (a derivative holding)SEC Form 45 January 2026Stock option (right to buy) · traded 31 December 2025 · filed 5 January 2026
- exercised options over 8,125 shares of Galectin Therapeutics (a derivative holding)SEC Form 45 January 2026Stock option (right to buy) · traded 31 December 2025 · filed 5 January 2026
- exercised options over 8,125 shares of Galectin TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- ▼ sold on the open market 8,125 shares of Galectin TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- exercised options over 6,463 shares of Galectin Therapeutics (a derivative holding)SEC Form 419 December 2025Stock option (right to buy) · traded 17 December 2025 · filed 19 December 2025
- exercised options over 8,500 shares of Galectin Therapeutics (a derivative holding)SEC Form 419 December 2025Stock option (right to buy) · traded 17 December 2025 · filed 19 December 2025
- ▼ sold on the open market 4,479 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- exercised options over 6,463 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- ▼ sold on the open market 6,463 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- exercised options over 8,500 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- ▼ sold on the open market 8,500 shares of Galectin TherapeuticsSEC Form 419 December 2025Common Stock · traded 17 December 2025 · filed 19 December 2025
- exercised options over 41,500 shares of Galectin Therapeutics (a derivative holding)SEC Form 414 November 2025Stock option (right to buy) · traded 13 November 2025 · filed 14 November 2025
- exercised options over 41,500 shares of Galectin Therapeutics (a derivative holding)SEC Form 414 November 2025Stock option (right to buy) · traded 13 November 2025 · filed 14 November 2025
- exercised options over 16,250 shares of Galectin Therapeutics (a derivative holding)SEC Form 414 November 2025Stock option (right to buy) · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 21,867 shares of Galectin TherapeuticsSEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- exercised options over 41,500 shares of Galectin TherapeuticsSEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 41,500 shares of Galectin TherapeuticsSEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- exercised options over 41,500 shares of Galectin TherapeuticsSEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 41,500 shares of Galectin TherapeuticsSEC Form 414 November 2025Common Stock · traded 13 November 2025 · filed 14 November 2025
- exercised options over 16,250 shares of Galectin TherapeuticsSEC Form 414 November 2025Common stock · traded 13 November 2025 · filed 14 November 2025
- ▼ sold on the open market 16,250 shares of Galectin TherapeuticsSEC Form 414 November 2025Common stock · traded 13 November 2025 · filed 14 November 2025
- was granted 65,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 427 January 2025Stock Option (right to buy) · traded 23 January 2025 · filed 27 January 2025
- was granted 60,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 427 January 2025Restricted Stock Unit · traded 23 January 2025 · filed 27 January 2025
- exercised options over 40,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 426 December 2024Restricted Stock Units · traded 23 December 2024 · filed 26 December 2024
- exercised options over 40,000 shares of Galectin TherapeuticsSEC Form 426 December 2024Common Stock · traded 23 December 2024 · filed 26 December 2024
- ▼ sold on the open market 13,654 shares of Galectin TherapeuticsSEC Form 426 December 2024Common Stock · traded 23 December 2024 · filed 26 December 2024
- was granted 100,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 45 August 2024Stock Option (right to buy) · traded 1 August 2024 · filed 5 August 2024
- was granted 10,000 shares of Galectin Therapeutics (a derivative holding)SEC Form 45 August 2024Restricted Stock Unit · traded 1 August 2024 · filed 5 August 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.